Oral Biolife, a biotechnology firm specializing in therapies for
dental diseases, has announced the publication of a groundbreaking
study in the journal ACS Applied Materials & Interfaces
journal. The research highlights the efficacy of the company's
primary asset, PiezoGEL™, an innovative injectable piezoelectric
hydrogel. The study demonstrated PiezoGEL™'s capability to
effectively treat periodontal disease in animal models, showcasing
significant reductions in pathogenic biofilm and promoting bone
tissue regeneration. Founders and scientific experts laud the
hydrogel's potential as a transformative solution for non-surgical
periodontal treatment, emphasizing its unique antimicrobial and
bone regeneration properties.
MIAMI
BEACH, Fla., Sept. 27,
2023 /PRNewswire-PRWeb/ -- Oral Biolife is
a biotechnology company committed to the discovery and development
of pioneering therapies for the treatment of dental diseases for
humans and companion animals. Today, we announce the publication of
a manuscript entitled "A Novel Injectable Piezoelectric Hydrogel
for Periodontal Disease Treatment" in the latest issue of ACS
Applied Materials & Interfaces. This work demonstrated the
ability of the Company's lead asset, PiezoGEL™, to treat
periodontal disease in a complex animal model.
This study further confirms that PiezoGEL™
should be a most promising and novel therapeutic candidate for the
non-surgical treatment of periodontal disease.
Periodontal disease is a multifactorial, bacterially induced
inflammatory condition characterized by the progressive destruction
of periodontal tissues.
For the first time, in this study, an injectable piezoelectric
hydrogel (PiezoGEL™) was developed after combining gelatin
methacryloyl (GelMA) with biocompatible piezoelectric fillers of
barium titanate (BTO) that produce electrical charges when
stimulated by biomechanical vibrations (e.g., mastication,
movements). PiezoGEL™ showed significant reductions in pathogenic
biofilm biomass (∲41%), metabolic activity (∲75%), and the number
of viable cells (∲2–3‥log) compared to hydrogels without BTO
fillers in vitro. Molecular analysis related the antibacterial
effects to be associated with reduced cell adhesion (downregulation
of porP and fimA) and increased oxidative stress (upregulation of
oxyR) genes. Moreover, PiezoGEL™ was demonstrated to significantly
enhance bone marrow stem cell (BMSC) viability and osteogenic
differentiation by upregulating RUNX2, COL1A1, and ALP.
Dr. Stella K. Vnook, MBA, PhD,
Founder of Oral Biolife stated: "This is a great Proof of Concept
that PiezoGEL™ is well positioned to potentially transform
periodontal treatment and potentially other areas where bone
regeneration and tissue growth are vital for recovery. The
scientific inventors of this technology, Dr. Santiago Orrego, PhD, and Dr. Carolina Montoya, PhD, have done a prodigious
job demonstrating how PiezoGEL™ effectively reduced periodontal
inflammation and increased bone tissue regeneration compared to
control groups in multiple mice models."
Bill Breitenbach, CEO of Oral
Biolife, commented: "We are very excited this study further
confirms that PiezoGEL™ may be a most promising and novel
therapeutic candidate for the non-surgical treatment of periodontal
disease".
This work provides further evidence that PiezoGEL™ is a
potentially groundbreaking disruptive treatment for periodontitis
due to its unique combination of antimicrobial and bone
regeneration properties.
About PiezoGEL™:
PiezoGEL™ is a piezoelectric hydrogel that is being developed
for use in the treatment of periodontal disease, a common dental
disease characterized by the formation of bacterial biofilms,
inflammation, bone loss, and if left untreated, loss of teeth.
PiezoGEL™ utilizes the ability of naturally occurring piezoelectric
materials to generate small electrical charges to elicit a combined
antimicrobial and bone tissue regenerative effect. Activation of
the piezoelectric materials in PiezoGEL™ have now been demonstrated
in a complex physiologic system to disrupt bacterial biofilms,
prevent bacterial recolonization as well as stimulate the regrowth
of the bone tissue that is lost due to periodontitis.
Advantages of PiezoGEL™:
- A cutting-edge, fundamentally different product compared to
existing non-surgical treatments /adjuvants.
- PiezoGEL™ is an innovative, drug-free treatment that does not
raise concerns regarding bacterial antibiotic resistance.
- Possess the unique ability to disrupt biofilms, prevent the
recolonization of bacteria, and stimulate the regrowth of bone
tissue without surgery
- Harnesses the benefits of piezoelectric particles and hydrogels
(light-curable, conforms to pocket spaces, and is biocompatible),
eliciting the desired biological processes in the periodontal
pocket that fight disease and generate tissue without surgery.
- PiezoGEL™'s bioactive effects have a long-term operation since
electrical charges are not exhausted and do not require
"re-charging".
About Oral Biolife
Oral Biolife is an innovative biotechnology company out of
Temple University that utilizes the
unique properties of Piezo materials to develop groundbreaking,
first-to-market products. Their lead asset, PiezoGEL™, via its
unique combination of antimicrobial and bone regeneration
properties, represents a potential breakthrough advancement for the
treatment of periodontal disease.
The publication can be found at the following link:
https://pubs.acs.org/doi/full/10.1021/acsami.3c08336.
Forward-Looking Statements:
THIS PRESS RELEASE MAY CONTAIN FORWARD-LOOKING STATEMENTS AND
INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS
BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING
STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND
INFORMATION CURRENTLY AVAILABLE TO THE COMPANY'S MANAGEMENT. WHEN
USED IN THE OFFERING MATERIALS, THE WORDS "ESTIMATE," "PROJECT,"
"BELIEVE," "ANTICIPATE," "INTEND," "EXPECT" AND SIMILAR EXPRESSIONS
ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH
CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT
MANAGEMENT'S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE
SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY'S
ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE
FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE
UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK
ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT
UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING
STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO
REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.
Media Contact
Bill Breitenbach, Oral Biolife
Inc., 1 215-707-3817, bill.breitenbach@oralbiolife.com,
https://www.oralbiolife.com
Stella Vnook, Oral Biolife Inc.,
1 215-707-3817, skvnook@gmail.com, https://www.oralbiolife.com
View original content to download
multimedia:https://www.prweb.com/releases/oral-biolife-announces-the-publication-of-a-pivotal-manuscript-demonstrating-the-efficacy-of-piezogel-for-the-treatment-of-periodontal-disease-in-vivo-301940277.html
SOURCE Oral Biolife Inc.